Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain

Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy for many womens health-related conditions, including gynecologic pain. This 7-day study of individuals living with endometriosis, adenomyosis, or chronic pelvic inflammatory disease (PID), will identify specific targets and mechanisms underlying the potential impact of a hemp-derived, full-spectrum, high-CBD product in individuals with gynecologic pain.

NCT Number	NCT07728695
Lead Sponsor	Staci Gruber, Ph.D. Collaborators: National Center for Complementary and Integrative Health (NCCIH)
Conditions	Endometriosis, Adenomyosis, Chronic Pelvic Inflammatory Disease
Enrollment	60 participants
Start Date	2026-09
Primary Completion	2029-01 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-27